The FDA has approved Genentech’s Susvimo (ranibizumab) to treat patients with diabetic retinopathy (DR). This is the third FDA-approved indication for Susvimo, which is also approved for treating wet age-related macular degeneration and diabetic macular edema.

Diabetic retinopathy affects almost 10 million people in the United States. It can lead to diabetic macular edema, which is a leading cause of vision loss. Diabetic retinopathy is characterized by microvascular damage to the blood vessels in the retina, often caused by poor blood sugar control in people with diabetes.

Susvimo provides continuous delivery of a customized formulation of ranibizumab through a refillable ocular implant. The Port Delivery Platform is surgically inserted into the eye during a one-time, outpatient procedu

See Full Page